Photo and text: OSI

On 23 May, the leadership of the Latvian Institute of Organic Synthesis (LIOS) and the Latvian Biomedical Research and Study Centre (BMC) met with their International Advisory Boards to present progress on the merger of both institutions into a single national research powerhouse, launching in 2026. With over 350 researchers and 200 students,  the new institute will strengthen Latvia’s scientific impact and international competitiveness.

For the second consecutive year, the International Advisory Boards of both LIOS and BMC have been closely following the institutes’ activities and the merger process, offering recommendations for improvements and directions for further development. The Boards comprise international scientists, industry experts, representatives of Latvian research universities, the Trade Union of Science and Education Workers, and science policy makers. The presence of such advisory structures reflects best international practice in research governance.

“The integration process has already been underway for two years – it is a slow and meticulous process that requires the careful evaluation of every function, to ensure that upon merging, we become even more efficient and better aligned with the needs of our researchers,” said Dace Kārkle, Director of LIOS. “Collaboration and consultation with the International Advisory Boards of both institutes is highly valuable, as it helps us to adopt a broader perspective and to draw on the experience of our respected international colleagues.”

All levels of governance have been carefully reviewed throughout the merger process, with a focus on identifying the most effective solutions to ensure an optimal and productive working environment for researchers. As a result, scientists will have access to the combined infrastructure and research resources of both institutes, further enhancing the institute’s capacity to attract international talent.

“By joining forces, two of Latvia’s leading research institutes will gain greater influence and weight when applying for project funding at both national and European levels. Innovative scientific work, in turn, is a benefit to Latvian society, helping to drive the country’s economic development,” emphasised Jānis Kloviņš, Chair of the BMC Scientific Council.

Reflecting on the achievements of LIOS and BMC on the path towards establishing a joint institute, Andres G. Fernandez, member of the International Advisory Board and expert in the biopharmaceutical industry, noted after the joint meeting: “It was truly impressive to witness the progress made in such a complex process, in preparation for the launch of a new institute in 2026. The outstanding scientific quality and clear synergy between the two institutions will undoubtedly serve as a strong driver for attracting top-level talent.”